comelofion befween Sloofamiry profeins and menal cell carcinoma Pospibility of early diagnsis and malecular targeeing therapy

本研究旨在分析S100A10、Anneal II和脑型脂肪酸结合蛋白(B-FABP)基因在肾癌中的表达及其作为肿瘤标志物和分子靶向治疗的潜在价值。在肾癌、S100A10和Annexin免疫组化染色的组织切片中，肿瘤组织中各基因或蛋白的表达均显著高于正常组织。然而，在正常肾上皮细胞中，这两种抗原均通过集合管系统表达于肾包膜和Henle‘s环的小管中，而在大多数肾细胞癌起源的近端小管中未见表达。有趣的是，S100A10和Annexin IF在所有肾细胞癌切片中均有染色，而与核级别和分期无关。这一结果使我们可以讨论，除了肿瘤的侵袭和转移外，它们还可能存在血管抑素。B-FABP在正常肾组织切片中未见表达，而在ACC组织切片中表达于细胞质中。肾细胞癌患者切除的肾组织中表达转录本ZRB-FABP，而非癌组织中未表达。此外，逆转录聚合酶链式反应(RT-PCR)未扩增出B-FABP基因片段和S100A10基因。然而，在手术前收集的患者尿样中扩增出B-FABP基因。结论B-FABP是一种新的标记物，S100A10也是一种很有前景的标记物。我们将提供一种新的从尿液中检测肾癌的免疫层析法试剂盒。

This study aimed to analyze expression of S100A10, anneal II and brain-type fatty acid binding protein (B-FABP) genes in renal cell carcinoma (RCC) and their potential value as tumor markers and molecular targeting therapy. Expression of each gene or protein in the tumor than that in the normal tissues was significantly increased In the tissue sections of RCC, S100A10 and annexin If were immunostained in membranes. In the normal renal epithelia, however, both antigens were stained in the Bowman's capsule and the tubules from Henle's loop through the collecting duct system, but not in the proximal tubules, from where most RCC are derived We decided that both antigens was not suitable as a candidate for molecular targeting therapy. Interestingly, S100A10 and annexin If were stained in all RCC sections regardless of nuclear grade and stage. This result allowed us to discuss that except for tumor invasion and metastasis, they also have the possibility of angiostatin. We am further required for new approachNo B-FABP was immunohistochemically detected in normal kidney sections, but it was stained in the cytoplasm of ACC tissue sections. The carcinoma tissues but not the noncancerous parts of the kidney samples resected from patients with RCC expressed the transcript Zr B-FABP. Furthermore the B-FABP cDNA fragment as well as S100A10 was not amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) in the urine samples of healthy donors or patients with RCC after surgical operation. However, B-FABP cDNA was amplified in the patient's urine samples collected before surgery. The minimum urine sample volume in RT-PCR is 500 uLIn conclusion, B-FABP is a novel marker and S100A10 is also promising marker Zr RCC. We would provide the new detection kit of RCC from urine using immunochromatography.